(:TPTX)

Aug 16, 2022 06:59 am ET
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Th
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the receipt of merger control clearance from the Federal Cartel Office of Germany (“FCO”), in connection with
Aug 08, 2022 04:17 pm ET
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended June 30, 2022 and provided...
Jul 27, 2022 04:05 pm ET
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the U.S. Food and Drug...
Jul 11, 2022 09:00 am ET
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HMTV, MANT, PCSB, TPTX
NEW YORK, July 11, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 09, 2022 07:11 pm ET
Lifshitz Law PLLC Announces Investigation of PLD, RFP, DRE and TPTX
Prologis, Inc. (NYSE: PLD) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of Prologis with Duke Realty Corporation. Under the terms of the agreement, Duke shareholders will...
Jul 06, 2022 09:23 pm ET
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HMTV, MANT, PCSB, TPTX
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hemisphere Media Group, Inc. (NASDAQ:...
Jul 05, 2022 07:48 pm ET
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Turning Point Therapeutics, Inc. (NASDAQ: TPTX) to Bristol Myers Squibb for $76.00 per share is fair to Turning Point shareholders.
Jul 05, 2022 07:32 pm ET
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics,
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Turning Point Therapeutics, Inc. (NasdaqGS: TPTX) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Turning Point will receive only $76.00 in cash for each share of Turning Point that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jun 28, 2022 08:56 am ET
TPTX Stock Alert: Halper Sadeh LLP is Investigating Whether the Sale of Turning Point Therapeutics, Inc. is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Turning Point Therapeutics, Inc. (NASDAQ: TPTX) to Bristol Myers Squibb for $76.00 per share is fair to Turning Point shareholders. Halper Sadeh encourages Turning...
Jun 27, 2022 09:00 am ET
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, PLD, RADA
NEW YORK, June 27, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 24, 2022 09:00 am ET
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD Anderson Cancer Center today announced a strategic...
Jun 22, 2022 08:09 pm ET
Lifshitz Law PLLC Announces Investigation of SIMO, CTT, TPTX, and SWCH
Silicon Motion Technology Corporation (NASDAQ: SIMO) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of SIMO to MaxLinear, Inc. for $93.54 in cash and 0.388 shares of MaxLinear...
Jun 22, 2022 01:30 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, ELSE, PLD
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Turning Point Therapeutics, Inc....
Jun 20, 2022 09:00 am ET
SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Investigates TPTX, DRE, ELSE, PLD
NEW YORK, June 20, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 18, 2022 07:17 pm ET
Lifshitz Law PLLC Announces Investigation of SIMO, CTT, TPTX, and SWCH
Silicon Motion Technology Corporation (NASDAQ: SIMO) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of SIMO to MaxLinear, Inc. for $93.54 in cash and 0.388 shares of MaxLinear...
Jun 14, 2022 09:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates TPTX, MANT, CDEV, CTT
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Turning Point Therapeutics, Inc....
Jun 13, 2022 07:05 pm ET
Lifshitz Law PLLC Announces Investigation of VSAT, CTT, TPTX, and SWCH
Viasat, Inc. (NASDAQ: VSAT) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the proposed acquisition of Inmarsat by VSAT. Under the terms of the Merger Agreement Inmarsat’s shareholders would...
Jun 13, 2022 09:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates PCSB, TPTX, MUDS, CTT
NEW YORK , June 13, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 10, 2022 06:00 pm ET
Investor Alert - The M&A Class Action Firm Announces an Investigation of Turning Point Therapeutics, Inc. - TPTX
NEW YORK, June 10, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Turning Point Therapeutics, Inc. (TPTX), relating to its proposed acquisition by Bristol-Meyers Squibb Co. Under the terms of the agreement, TPTX shareholders will receive $76.00 in cash per share they own. Click here for more information
Jun 07, 2022 07:36 pm ET
Lifshitz Law PLLC Announces Investigation of VSAT, CTT, TPTX, and SWCH
Viasat, Inc. (NASDAQ: VSAT) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the proposed acquisition of Inmarsat by VSAT. Under the terms of the Merger Agreement Inmarsat’s shareholders would...
Jun 07, 2022 09:41 am ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates HMTV, TPTX, SAIL
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hemisphere Media Group, Inc. (NASDAQ:...
Jun 06, 2022 02:19 pm ET
TURNING POINT THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of TPTX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Turning Point Therapeutics, Inc. (NASDAQ: TPTX) breached their fiduciary duties or violated...
Jun 06, 2022 09:06 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Turning Point Therapeutics, Inc. (Nasdaq - TPTX), UB Bancorp (OTC - UBNC), Sprague Resources LP (NYSE - SRLP),
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jun 06, 2022 09:00 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLP Investigates VMW, TPTX, CTT, TXMD
NEW YORK, June 6, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 05, 2022 10:44 pm ET
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics,
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Turning Point Therapeutics, Inc. (NasdaqGS: TPTX) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Turning Point will receive only $76.00 in cash for each share of Turning Point that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jun 03, 2022 02:12 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Turning Point Therapeutics, Inc.
NEW YORK, June 3, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Turning Point Therapeutics, Inc. ("Turning Point" or the "Company") (NASDAQ: TPTX), in connection with the proposed acquisition of the Company by Bristol-Myers Squibb Company (NYSE: BMY) via a tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $76.00 in cash for each share of Turning Point common stock owned. The transaction is valued at approximately $4.1 billion.
Jun 03, 2022 12:01 pm ET
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Turning Point Therapeutics, Inc. (NASDAQ: TPTX) to Bristol Myers Squibb for $76.00 per share is fair to Turning Point shareholders.
Jun 03, 2022 10:00 am ET
Shareholder Alert: Ademi LLP investigates whether Turning Point Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myer
MILWAUKEE, June 3, 2022 /PRNewswire/ -- Ademi LLP is investigating Turning Point Therapeutics (NASDAQ:TPTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myer. 
Jun 03, 2022 09:31 am ET
Thinking about buying stock in Turning Point Therapeutics, Amylyx Pharmaceuticals, Society Pass, Chegg, or Solo Brands?
NEW YORK, June 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TPTX, AMLX, SOPA, CHGG, and DTC.
May 26, 2022 04:30 pm ET
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced that President and CEO Athena Countouriotis, M.D., will participate...
May 16, 2022 08:30 am ET
Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer,...
May 10, 2022 04:05 pm ET
Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended March 31, 2022 and provided...
May 10, 2022 08:30 am ET
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the U.S. Food and Drug Administration (FDA) granted an eighth...
May 05, 2022 09:00 am ET
Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced today that it has entered into an exclusive license agreement with LaNova...
Apr 28, 2022 07:30 am ET
Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative,...
Apr 28, 2022 07:30 am ET
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Zai Lab (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation...
Apr 12, 2022 04:46 pm ET
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced positive topline results from the registrational TRIDENT-1...
Mar 29, 2022 09:00 am ET
Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior...
Mar 21, 2022 08:00 am ET
Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the company has achieved its enrollment target of 40 patients...
Mar 09, 2022 04:05 pm ET
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced its participation in the following investor conferences: March 15, 34th...
Mar 07, 2022 05:00 pm ET
Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference - Update
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that due to a conference schedule change, the fireside chat with President and...
Mar 01, 2022 04:05 pm ET
Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a...
Feb 28, 2022 04:02 pm ET
Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the fourth quarter and year ended December 31, 2021, and...
Feb 02, 2022 09:00 am ET
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the...
Jan 20, 2022 09:00 am ET
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cance
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the company has received clearance from the FDA for the company’s...
Jan 18, 2022 09:00 am ET
Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today provided updates and anticipated milestones across its 2022 strategic objectives. “As...
Jan 18, 2022 06:16 am ET
Syneos Health Appoints Two New Independent Directors
Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors. “We are excited...
Dec 20, 2021 08:00 am ET
Turning Point Therapeutics Provides Regulatory Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced regulatory updates for its lead drug candidate, repotrectinib, a ROS1/TRK...
Nov 10, 2021 04:01 pm ET
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the...
Nov 09, 2021 04:01 pm ET
Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided...
Nov 08, 2021 04:01 pm ET
Turning Point Therapeutics Announces Appointment of Adam Levy as Senior Vice President of Investor Relations
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Adam Levy, Ph.D., MBA, as senior vice president of Investor...
Nov 02, 2021 04:01 pm ET
Turning Point Therapeutics to Host Third Quarter 2021 Conference Call
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will report third quarter financial results following the close of...
Oct 23, 2021 09:12 am ET
Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the presentation of early clinical data from the ongoing Phase 1/2 CARE study...
Oct 13, 2021 04:01 pm ET
Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Ca
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and EQRx, a new type of pharmaceutical company committed to developing and delivering...
Oct 11, 2021 04:05 pm ET
Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will present early clinical data for repotrectinib from the ongoing...
Oct 08, 2021 08:30 am ET
Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the presentation of early clinical data from the NTRK-positive TKI-naïve and...
Oct 07, 2021 07:00 am ET
Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the presentation of additional preliminary clinical data from ongoing trials...
Oct 04, 2021 09:00 am ET
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the U.S. Food and Drug Administration (FDA) granted a seventh regulatory...
Sep 30, 2021 04:30 pm ET
Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced additional details for its data presentations, including a late-breaking...
Sep 08, 2021 04:05 pm ET
Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conferenc
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced a late-breaker abstract of early clinical data by physician assessment for...
Sep 01, 2021 09:00 am ET
Turning Point Therapeutics to Participate In Upcoming Investor Conferences
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the...
Aug 16, 2021 09:00 am ET
Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced initiation of the first cohort of its Phase 1b/2 TRIDENT-2 combination study...
Aug 11, 2021 04:01 pm ET
Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the U.S. Food and Drug Administration (FDA) granted a sixth regulatory...
Aug 09, 2021 04:02 pm ET
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results and operational updates for the second quarter ended June 30,...
Jul 28, 2021 04:15 pm ET
Turning Point Therapeutics to Host Second Quarter 2021 Conference Call
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report second quarter financial results following the close of U.S. financial markets on...
Jun 29, 2021 09:00 am ET
Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Tombesi...
Jun 17, 2021 08:30 am ET
Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that TPX-0022, the company’s inhibitor of MET and the associated cancer...
Jun 01, 2021 09:00 am ET
Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a...
May 25, 2021 09:00 am ET
Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its...
May 17, 2021 09:00 am ET
Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president...
May 05, 2021 04:05 pm ET
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results and operational updates for the first quarter ended March 31,...
Apr 26, 2021 09:00 am ET
Turning Point Therapeutics to Host First Quarter 2021 Conference Call
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report first quarter financial results following the close of U.S. financial markets on...
Apr 12, 2021 09:00 am ET
Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced initiation of its Phase 1/2 FORGE-1 study of TPX-0131, a potent inhibitor of...
Apr 09, 2021 09:00 am ET
Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced new preclinical data supporting the ongoing development of three of its drug...
Apr 05, 2021 04:01 pm ET
Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported initial clinical data from the ongoing Phase 1/2 SWORD-1 study of its RET...
Mar 31, 2021 04:05 pm ET
Turning Point Therapeutics Announces Board Changes
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the addition of Barbara Bodem to its board of directors. Ms. Bodem brings...
Mar 10, 2021 06:08 pm ET
Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced today that four abstracts featuring three of its drug candidates will be presented...
Mar 04, 2021 09:00 am ET
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced its participation in the following investor conferences: March 9, H.C....
Mar 01, 2021 04:02 pm ET
Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results and operational updates for the fourth quarter and year ended...
Feb 18, 2021 09:00 am ET
Turning Point Therapeutics to Host Fourth Quarter and Full-Year 2020 Conference Call
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report fourth quarter and year ended Dec. 31, 2020 financial results following the close...
Feb 04, 2021 08:30 am ET
Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the...
Jan 29, 2021 08:30 am ET
Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced updated interim findings from the ongoing TRIDENT-1 registrational study of lead...
Jan 11, 2021 07:40 am ET
Turning Point Therapeutics Announces 2021 Milestone Targets
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced 2021 milestone targets for its pipeline of four drug candidates, including...
Jan 11, 2021 06:45 am ET
Turning Point and Zai Lab Broaden Collaboration
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical...
Jan 11, 2021 04:30 am ET
Turning Point and Zai Lab Broaden Collaboration
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical...
Dec 08, 2020 08:30 am ET
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced its lead drug candidate, repotrectinib, has been granted breakthrough therapy...
Nov 12, 2020 04:05 pm ET
Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results and operational updates for the third quarter ended Sept. 30....
Nov 10, 2020 04:30 pm ET
Turning Point Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will present a company...
Oct 29, 2020 04:15 pm ET
Turning Point Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the closing of its previously announced underwritten public offering of...
Oct 26, 2020 11:33 pm ET
Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock
Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of...
Oct 26, 2020 07:00 am ET
Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock
Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it has commenced an underwritten public offering, subject to market and...
Oct 24, 2020 10:15 am ET
Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported initial clinical data from the ongoing Phase 1 dose finding portion of its...
Oct 22, 2020 08:00 am ET
Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced it will host a conference call and webcast on Sat., Oct. 24 at 11:00 a.m. ET...
Oct 21, 2020 08:00 am ET
Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that an abstract for the TRIDENT-1 clinical study of its lead drug candidate...
Oct 07, 2020 07:45 am ET
Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that abstracts submitted for two of its drug candidates have been selected for...
Sep 30, 2020 09:00 am ET
Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a...
Sep 21, 2020 09:00 am ET
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two...
Sep 01, 2020 09:00 am ET
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in...
Aug 31, 2020 09:00 am ET
Turning Point Therapeutics Announces Scientific Advisory Board
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the formation of a scientific advisory board to help guide the company’s early...
Aug 24, 2020 08:30 am ET
Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the Food and Drug Administration (FDA) granted a third Fast-Track designation...
Aug 19, 2020 07:00 am ET
Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported early interim data from the registrational Phase 2 TRIDENT-1 study of lead drug...
Aug 10, 2020 08:30 am ET
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results and operational updates for the second quarter ended June 30....
Jul 27, 2020 09:00 am ET
Turning Point Therapeutics Names Heather Adams as Vice President of Human Resources
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Heather Adams as vice president of Human Resources,...
Jul 13, 2020 09:00 am ET
Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Andrew Partridge as executive vice president and chief...
Jul 07, 2020 07:30 am ET
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today...
Jul 07, 2020 07:30 am ET
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today...
Jun 22, 2020 09:00 am ET
Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today presented preclinical studies highlighting the potential for its lead drug candidate,...
Jun 01, 2020 09:00 am ET
Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare Conference Webcast
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate via...
May 29, 2020 08:10 am ET
Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today at the ASCO Annual Meeting presented a preclinical update for its novel, clinical-stage,...
May 27, 2020 08:30 am ET
Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the underwriters of its previously announced underwritten public offering...
May 18, 2020 08:52 pm ET
Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock
Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of...
May 18, 2020 07:00 am ET
Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock
Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it has commenced an underwritten public offering, subject to market and...
May 12, 2020 04:45 pm ET
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the first quarter ended Mar. 31 and provided operational...
May 04, 2020 09:00 am ET
Turning Point Therapeutics to Host First Quarter Conference Call
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report first quarter financial results following the close of U.S. financial markets on...
Apr 16, 2020 09:00 am ET
Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment-Naïve and Solvent-Front Mutation Ros1-Positive Non-Small Cell Lung Cancer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the publication of preclinical data and patient case studies from the Phase 1...
Mar 16, 2020 09:00 am ET
TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial and operational highlights for the fourth quarter and year-ended Dec....
Mar 02, 2020 08:00 am ET
Turning Point Therapeutics to Host Fourth-Quarter, Full-Year 2019 Conference Call
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report fourth quarter and 2019 financial results following the close of U.S. financial...
Feb 20, 2020 09:00 am ET
Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Siegfried Reich, Ph.D. as executive vice president and...
Feb 18, 2020 09:00 am ET
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the 9th...
Feb 03, 2020 09:00 am ET
Turning Point Therapeutics to Participate in Guggenheim Oncology Day
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a...
Jan 23, 2020 09:00 am ET
Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson...
Jan 13, 2020 09:00 am ET
Turning Point Therapeutics Announces Program Updates and Milestones for 2020
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today provided program updates for its four drug candidates and ongoing clinical studies....
Jan 09, 2020 05:00 pm ET
Turning Point Therapeutics Announces Management Transition
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that Dr. Jean Cui will step down as the company’s chief scientific officer for...
Jan 06, 2020 09:00 am ET
Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Homa Yeganegi as senior vice president, project team leader and head of Medical...
Dec 17, 2019 09:00 am ET
Turning Point Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in a...
Nov 13, 2019 08:30 am ET
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in the Jefferies 2019 London...
Nov 12, 2019 08:30 am ET
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead drug candidate repotrectinib in pediatric...
Nov 11, 2019 08:30 am ET
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its drug candidate TPX-0046 in patients with advanced...
Nov 04, 2019 04:05 pm ET
Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today reported financial and operational highlights for the third quarter ended Sept. 30. President and Chief...
Oct 21, 2019 06:00 am ET
Turning Point Therapeutics to Host Third Quarter 2019 Conference Call
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report third quarter financial results following the close of U.S. financial markets on Nov. 4 and host a...
Sep 30, 2019 08:30 am ET
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug...
Sep 05, 2019 08:34 pm ET
Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock
Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the pricing of its public offering of 4,500,000 shares of common stock at a price to the public of...
Sep 03, 2019 04:14 pm ET
Turning Point Therapeutics Announces Proposed Public Offering of Common Stock
Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced today it has filed a registration statement on Form S-1 with the Securities and Exchange Commission...
Sep 03, 2019 04:01 pm ET
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced updated interim data from the Phase 1 portion of its ongoing Phase 1/2 TRIDENT-1 clinical study of...
Aug 28, 2019 09:00 am ET
Turning Point Therapeutics Participate in Upcoming Investor Conferences
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in the 2019 Wells Fargo Healthcare...
Aug 06, 2019 04:05 pm ET
Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today reported financial and operational highlights for the second quarter ended June 30. “During the second...
Jul 31, 2019 04:30 pm ET
Turning Point Therapeutics’ CEO to Present at Canaccord Genuity 39th Annual Growth Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at...
Jul 31, 2019 08:30 am ET
Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1 clinical study of patients with advanced solid tumors harboring genetic...
Jul 29, 2019 08:30 am ET
Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today named Yi Larson as executive vice president and chief financial officer, effective Aug. 26. Ms. Larson joins...
Jul 25, 2019 08:30 am ET
Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the appointment of Carol Gallagher, Pharm.D. to its board of directors. Dr. Gallagher brings...
Jul 22, 2019 09:00 am ET
Turning Point Therapeutics to Host Second Quarter 2019 Conference Call
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report second quarter financial results following the close of U.S. financial markets on Aug. 6 and host a...
Jun 20, 2019 09:00 am ET
Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of the registrational Phase 2 portion of its TRIDENT-1 clinical study of patients with...
Jun 04, 2019 08:30 am ET
Turning Point Therapeutics’ CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at...
May 31, 2019 08:30 am ET
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced updated interim data from its ongoing Phase 1/2 TRIDENT-1 clinical study of lead drug candidate...
May 15, 2019 09:00 am ET
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs that address treatment resistance, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug (IND)...
May 14, 2019 04:30 pm ET
Turning Point Therapeutics' CEO to Present at UBS Healthcare Conference
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs that address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in...
May 14, 2019 09:00 am ET
Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. to Its Board of Directors
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the appointment of Patrick Machado, J.D. to its board of directors. Mr. Machado brings more than...
May 06, 2019 09:00 am ET
Turning Point Therapeutics and Almac Diagnostic Services Announce Approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, and Almac Diagnostic Services, a global stratified medicine company, today announced approval by the U.S. Food and...
Apr 22, 2019 04:05 pm ET
Turning Point Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Turning Point Therapeutics, Inc. (Nasdaq:TPTX), a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, today announced the closing of its initial public offering of 10,637,500 shares of its...
Apr 16, 2019 10:57 pm ET
Turning Point Therapeutics Announces Pricing of Initial Public Offering
Turning Point Therapeutics, Inc. (Nasdaq:TPTX), a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, today announced the pricing of its initial public offering of 9,250,000 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to Turning Point Therapeutics from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $166.5 million.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.